Every month, across India's pharmaceutical and medical device landscape, a familiar ritual plays out. Field representatives fan out to collect secondary sales statements from hundreds, sometimes thousands, of stockists. They return with a chaotic mix: blurry phone photos of printouts, PDFs in various formats, Excel files with inconsistent column widths, and handwritten notes scribbled in the margins.
What should be a straightforward data collection exercise turns into a month-long nightmare of reconciliation, validation, and firefighting.
The reality is stark: secondary sales data remains one of the largest blind spots in Indian pharma operations. And it's not for lack of trying.
The challenge isn't just about collecting data, it's about the sheer diversity of how that data arrives:
The human cost is equally troubling. Representatives who should be building doctor relationships and expanding market reach instead find themselves doing data entry. Managers lose sleep over incomplete submissions and data integrity issues. Analytics teams spend more time cleaning data than analyzing it.
The obvious solution seemed to be OCR technology. Extract text from documents automatically, eliminate manual entry, and solve the problem overnight.
Except it didn't work that way.
Traditional OCR-based solutions required manual format mapping for every stockist statement. With hundreds of stockists, each using different formats that changed periodically, the maintenance burden became unsustainable.
Even after extensive setup, coverage rarely exceeded 60-70%. The remaining statements still required manual processing, creating a two-track system that was arguably more complex than the original problem.
For companies seeking comprehensive market visibility, 70% coverage meant 30% blind spots potentially in the most critical territories. Data gaps led to incomplete analytics, resulting in a flawed strategy. The promise of automation remained frustratingly out of reach.
After years of watching pharmaceutical companies struggle with this challenge, Aurochs made a decision: solve this problem completely, or don't solve it at all.
Today, we're proud to introduce Salusa, a breakthrough secondary sales collection and analytics platform that finally delivers on the promise of automated, comprehensive, accurate secondary sales management.
Salusa isn't an incremental improvement over existing solutions. It's a fundamental reimagining of how secondary sales data should be collected, validated, and transformed into actionable business intelligence.
Built on cutting-edge AI technology and deep pharmaceutical domain expertise, Salusa makes secondary sales data collection effortless, accurate, and genuinely scalable, regardless of your stockist count, statement formats, or variations in data quality.
At the core of Salusa is a Visual Language Model (VLM) that represents a quantum leap beyond traditional OCR.
Where OCR sees pixels and attempts to match them to characters, VLMs understand context. They process both visual layout and semantic meaning, adapting to format variations the way a human would.
Format Flexibility Without Configuration
Upload a statement in any format, crisp PDF, photographed printout, Excel spreadsheet, or even a slightly blurred image taken in poor lighting. Salusa processes them all with equal accuracy. No pre-configuration. No format mapping. No training required for new stockist statement types.
Near-Perfect Coverage
While OCR-based solutions plateau at 60-70% stockist coverage, Salusa achieves near 100% coverage across all stockists. Every statement gets processed. Every data point gets captured. No blind spots.
Contextual Intelligence
VLMs don't just extract text, they understand what they're looking at. Column headers, product names, quantities, values, dates - Salusa identifies and categorizes information intelligently, even when layouts vary dramatically between statements.
This isn't theoretical. In deployment, Salusa processes statements from modern ERP systems and decades-old dot matrix printouts with equal accuracy. The technology adapts to your data reality, rather than forcing your data to conform to rigid templates.
Extracting data is only half the battle. The real challenge lies in making sense of it.
Stockist product names rarely match the company master data perfectly. A product officially named "Amoxicillin 500mg Capsule" might appear as "AMOX 500," "Amoxi Cap," or "Amoxycillin-500" across different stockist statements.
Traditional systems choke on these variations, creating orphaned entries that require manual reconciliation. Salusa handles them intelligently.
Salusa employs a sophisticated classification model that maps stockist entries to your product master with remarkable accuracy:
The result? What once required hours of tedious manual matching now happens in seconds, with accuracy that exceeds even experienced data operators.
The impact on daily operations is immediate and dramatic.
Before Salusa, processing a month's stockist statements could consume an entire afternoon or multiple days for representatives with large territories. Data entry, validation, email exchanges, corrections, resubmissions. With Salusa, representatives process their complete monthly stockist statements in under 20 minutes. Upload statements. Let the VLM extract and classify data. Quick validation review. Submit. Done.
When a task is painful, compliance suffers. When it's effortless, compliance becomes the default. Companies implementing Salusa report dramatic improvements in on-time submission rates. Representatives no longer dread month-end data collection. Managers no longer chase late submissions. The entire organization moves faster.
Every action is tracked. Every change is logged. Every modification is attributed.
This isn't just good practice, it's essential for regulatory compliance, internal audits, and data integrity verification. Salusa makes audit readiness automatic, not an afterthought.
Headquarters operations teams know the pain: weeks spent reconciling data discrepancies, tracking down missing statements, correcting manual-entry errors, and preparing data for analytics.
Salusa eliminates 90% of reconciliation work. Data arrives clean, structured, and validated. Analytics teams can focus on insights, not cleanup. Strategic planning happens from accurate baselines, not best guesses.
Data collection is never the end goal it's the foundation for insight. Salusa doesn't just collect data; it transforms it into intelligence.
The Salusa executive dashboard presents a comprehensive business view through intuitive visualizations:
Performance Metrics
Sales Trend Analysis
Inventory Intelligence
Product Performance Deep Dive
Salusa includes a comprehensive reporting suite designed for pharmaceutical business requirements:
Every report is available in both visual and tabular formats. One-click Excel export enables further custom analysis in familiar tools.
Pharmaceutical companies vary widely in structure, product portfolios, and business models. Salusa's data stack adapts seamlessly:
You don't adapt to the platform. The platform adapts to you.
The industry is moving from manual data collection with all its inefficiencies to intelligent automation that just works regardless of data format, stockist sophistication, or territory challenges.
No more reconciling disparate data sources, chasing missing submissions, or working with partial visibility. Salusa provides a single source of truth for secondary sales across your entire network.
Days or weeks of lag between data collection and actionable insights become same-day visibility. Market opportunities are captured, not missed. Problems are addressed proactively, not reactively.
When 90% of reconciliation work disappears, operations teams are liberated to focus on what matters: strategic planning, market intelligence, performance optimization, and growth initiatives.
For decades, pharmaceutical companies have accepted manual secondary sales collection as an unavoidable operational burden. Data quality issues, compliance challenges, delayed insights, and administrative overhead are all treated as the cost of doing business.
Salusa proves that acceptance was premature.
The technology exists today to eliminate these problems. To collect comprehensive secondary sales data effortlessly. To validate it automatically. To transform it into intelligence immediately. To free your field force and operations teams to focus on growth, not data entry.
The era of manual secondary sales collection is over.
The companies that recognize this and act quickly will gain significant competitive advantages: better market intelligence, faster decision-making, more efficient operations, and field teams focused on revenue generation rather than administrative tasks.
We invite pharmaceutical and medical device companies to see Salusa in action. Experience firsthand how VLM technology transforms statement processing. Explore the analytics capabilities. Understand the operational impact.
Your secondary sales data holds tremendous value if you can unlock it. Salusa is the key.
"With Salusa, your data works as fast as your market moves."
Ready to transform your secondary sales operations?
Contact Aurochs today to schedule a personalized demonstration or discuss how Salusa can be tailored to your specific business requirements.
Salusa is part of the Incentivate portfolio by Aurochs Solutions for pharmaceutical sales excellence.